<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

News

External stories on biodesix

Posts in: liquid biopsy

Clinical Lab Products: Predicting the Effectiveness of Anti-PD-L1 Therapy

In the study, ddPCR detected PD-L1 mRNAs with a dynamic range of 32–138 copies from plasma. If validated, such a test could offer additional information to physicians.

Clinical Lab Products: Overcoming Immune Blockade in Non-Small Cell Lung Cancer

Promising initial findings demonstrate the technical feasibility of the PD-L1 circulating blood test.

The Pathologist: Has Tumor Profiling Caught Up to Cancer?

Dr. Skibo discusses how ddPCR-based liquid biopsy could become an indispensable method for doctors to categorize a patient’s disease.

Clinical Lab Products: Blood-based Approach to PD-L1 Detection Shows Concordance with Immunohistochemistry

Clinical lab products article: Blood-Based Approach to PD-L1 Detection Shows Concordance with Immunohistochemistry. Comments from Dr. Pritchett, Dr. Niu

The Pathologist: Battling Lung Cancer in the Tobacco Belt

Dr. Paul Walker describes how liquid biopsy testing helps battling lung cancer in the tobacco belt. The advantages of liquid biopsy for lung cancer.

Medical Laboratory Observer: Rapid Biomarker Testing for Improved Clinical Decision-making in Non-small Cell Lung Cancer

Dr. Skibo discusses how ddPCR-based liquid biopsy could be the solution to treatment delays due to receiving genetic information late.

Clinical Lab Products: ROS1/RET Now Available in Liquid Biopsy Test

ROS1 and RET mutations are now available in Biodesix's liquid biopsy test, GeneStrat

Biodesix Launches GeneStrat Targeted Liquid Biopsy Mutation Test for Patients with Advanced Lung Cancer

Genestrat: a targeted liquid biopsy for patients with NSCLC. Blood test with 72 hour turnaround time.

Biodesix’s VeriStrat Test for Cancer Treatment Passes Phase 3 Trial (Xconomy)

Veristart passed a key clinical trial that shows it can give physicians a better idea of what to do next after the first round of treatment for NSCLC.

Putting Lung Cancer in the Bullseye (Breakthroughs)

Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. It all comes down to a blood test called VeriStrat.

1 2 3 Last